| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Epilepsy Research Center, Department of Neurology (Drs. Leppik and Graves, and T.L. Sierzant and M.P. Jacobs), University of Minnesota, Minneapolis, MN; Department of Neurology (Drs. Dreifuss, Drury, Bertram, Cooper, and Lee, and N. Santilli), Health Sciences Center, University of Virginia, Charlottesville, VA; Epilepsy Branch (Drs. Pledger, Tsay, Cereghino, Sahlroot, and Sheridan, and M. Ashworth), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and College of Pharmacy (Dr. Graves), University of Minnesota, Minneapolis, MN.
Felbamate (2-phenyl-1,3-propanediol dicarbamate) has a favorable preclinical profile in animal models of epilepsy. We present the results of a double-blind, randomized, placebo-controlled clinical trial in patients with partial seizures. Criteria for entry included a requirement for four or more partial seizures per month despite concomitant therapeutic blood levels of phenytoin and carbamazepine. Fifty-six patients (mean age, 31.4 years; 32 men, 24 women) completed the trial. The mean seizure frequencies for the 8-week periods analyzed were felbamate = 34.9, placebo = 40.2. Felbamate was statistically superior to placebo in seizure reduction, percent seizure reduction, and truncated percent seizure reduction. The mean felbamate dosage was 2,300 mg/d. Plasma felbamate concentrations ranged from 18.4 to 51.9 mg/l, mean = 32.5 mg/l. Adverse experiences during felbamate therapy were minor and consisted primarily of nausea and CNS effects. This trial indicates that felbamate is safe and effective in the treatment of comedicated patients with severely refractory epilepsy.
Address correspondence and reprint requests to Dr. Ilo E. Leppik, MINCEP Epilepsy Care, 5775 Wayzata Blvd., Suite 255, Minneapolis, MN 55416.
Supported by the NINDS, contract 81-2371 and grant NS-16308.
Received December 19, 1990. Accepted for publication in final form April 26, 1991.
This article has been cited by other articles:
|
|
 |
|
  S. M. LaRoche and S. L. Helmers The New Antiepileptic Drugs: Scientific Review JAMA, February 4, 2004; 291(5): 605 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Kuo, B.-J. Lin, H.-R. Chang, and C.-P. Hsieh Use-Dependent Inhibition of the N-Methyl-D-aspartate Currents by Felbamate: a Gating Modifier with Selective Binding to the Desensitized Channels Mol. Pharmacol., February 1, 2004; 65(2): 370 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-C. Egnell, B. Houston, and S. Boyer In Vivo CYP3A4 Heteroactivation Is a Possible Mechanism for the Drug Interaction between Felbamate and Carbamazepine J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1251 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Pellock Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs Pediatrics, November 1, 1999; 104(5): 1106 - 1116. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. French, M. Smith, E. Faught, and L. Brown Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology, May 1, 1999; 52(8): 1540 - 1540. [Full Text] [PDF]
|
|
|
|
|
|
R. T. McCabe, R. D. Sofia, R. T. Layer, K. A. Leiner, R. L. M. Faull, N. Narang, and J. K. Wamsley Felbamate Increases [3H]Glycine Binding in Rat Brain and Sections of Human Postmortem Brain J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 991 - 999. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Hosain, L. Nagarajan, D. Carson, G. Solomon, J. Mast, and D. Labar Felbamate for Refractory Infantile Spasms J Child Neurol, October 1, 1997; 12(7): 466 - 468. [PDF]
|
|
|
|
|
|
J. M. Rho, S. D. Donevan, and M. A. Rogawski Barbiturate-Like Actions of the Propanediol Dicarbamates Felbamate and Meprobamate J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1383 - 1391. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. D. Malan Pharmaceutical Care in a State Operated Mental Health and Developmental Disabilities Department Journal of Pharmacy Practice, August 1, 1996; 9(4): 229 - 246. [Abstract] [PDF]
|
|
|
|
 |
|
 C. G. Wasterlain, L. M. Adams, J. K. Wichmann, R. D. Sofia, and J. MacManus Felbamate Protects CA1 Neurons From Apoptosis in a Gerbil Model of Global Ischemia Stroke, July 1, 1996; 27(7): 1236 - 1240. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Dichter and M. J. Brodie New Antiepileptic Drugs N. Engl. J. Med., June 13, 1996; 334(24): 1583 - 1590. [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir and K. R. Lees Clinical Experience With Excitatory Amino Acid Antagonist Drugs Stroke, March 1, 1995; 26(3): 503 - 513. [Abstract] [Full Text]
|
|
|
|
|
|
O. Devinsky, B. Vazquez, and D. Luciano New Antiepileptic Drugs for Children: Felbamate, Gabapentin, Lamotrigine, and Vigabatrin J Child Neurol, October 1, 1994; 9(1_suppl): S33 - S45. [Abstract] [PDF]
|
|
|
|
|
|
The Felbamate Study Group in Lennox-Gastaut Syndro Efficacy of Felbamate in Childhood Epileptic Encephalopathy (Lennox-Gastaut Syndrome) N. Engl. J. Med., January 7, 1993; 328(1): 29 - 33. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
